Aurobac TherapeuticsAMR joint venture Aurobac appoints CEO Aurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance … more ➔
BioxodesBioxodes with management changes Bioxodes SA,based in Marche-en-Famenne, Belgium, has appointed Marc Dechamps as its new CEO. Company founder, Edmond Godfroid, will take up the post of Chief Operations Officer (COO) alongside his existing … more ➔
MaaT PharmaMaaT Pharma appointed new CSO French MaaT Pharma has appointed Nathalie Corvaïa as Chief Scientific Officer and will strengthens its R&D Activities in Immuno-Oncology. more ➔
MimetasMimetas: New Chair of the BoardLeiden-based Mimetas, specialist in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel (UCB, Belgium) as Chair of its Board of Directors. more ➔
Lytix BiopharmaLytix Biopharma: CBO-Position new filled Oslo-based Lytix Biopharma has a new Chief Business Officer. Stephen Worsley has started at the Norwegian immune-oncology company at the beginning of September. more ➔
CarbiosNew Head of Finance for Carbios Finance Expert Pascal Bricout strengthens French Carbios as Chief of Strategy; Financial Officer and a member of the Executive Committee. more ➔
Beckman CoulterNew president of Beckman Coulter Life Scie...Beckman Coulter Life Sciences announces that Suzanne Foster has been appointed as president of the company. She succeeds Greg Milosevich, who has left the company. more ➔
Andera Life SciencesStrengthening for Andera’s Life Scie...Jan Van den Bossche becomes the 20th partner of Andera Partners. He joined the Life Sciences team at the beginning of July to accelerate the deployment of its BioDiscovery 6 fund. more ➔
Charnwood MolecularCharnwood Molecular with new CEO Lee Patterson joins UK-based Charnwood Molecular as new CEO. After nearly 25 years at UK-based Charnwood Molecular, Prof. Steve Allin has stepping down as CEO. He will remain as an investor and Board … more ➔
